重组人干扰素α-1b治疗婴幼儿急性毛细支气管炎疗效及成本评价

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (606 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the therapeutic effect and treatment cost of recombinant human interferon α-1b on acute bronchiolitis in infants.Methods In this randomized and controlled clinical study, 70 children with acute bronchiolitis were divided into the study group and the control group with 35 cases each. The study group received recombinant human interferon α-1b [1 μg/(kg·d), 1 time/d, intramuscular injection] in addition to the conventional treatment. The control group received 50 ml saline and ribavirin [15 mg/(kg·d),twice, intravenous infusion] in addition to the conventional treatment. The total efficacy of the treatment on the two groups was compared. Coughing, wheezing, lung wheezes, crackles and days of hospitalization of the two groups were observed, and their treatment costs were statistically analyzed.Results The treatment efficacy in the study group was significantly higher than in the control group,with 97.2% and 82.8% respectively(χ²=19.78,P<0.05).All patients were cured. Hospitalization days were 4.09±1.21 and 7.54±1.59 in the study group and the controll group,respectively,with statistical significant difference. The disappearance time of symptoms and signs was significantly shorter and the treatment cost was significantly lower in the study group than in the control group (t=6.79,P<0.01).Conclusions Using recombinant human interferon α-1b as treatment of acute bronchiolitis can significantly improve the therapeutic effect and reduce the treatment cost.

Key words： bronchiolitis treatment cost recombinant human interferon α-1b ribavirin

Received: 15 June 2015

ZTFLH:

R725

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MENG Yajie
	LIANG Zhenlun
	ZHANG Qi
	CHEN Yan
	DING Haijun
	and YIE Caixia

Cite this article:

MENG Yajie,LIANG Zhenlun,ZHANG Qi等. Evaluation of therapeutic effect and cost of recombinant human interferon α-1b in treatment of acute bronchiolitis in infants[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(4): 373-375.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I4/373

[1]	Pelleier A J, Mansbach J M, Camargo C A. Direct medical costs of brochiolitis hospitalizations in the United States [J]. Pediatrics, 2006, 118(6): 2418-2423.
[2]	Hall C B. Respiratory syncytial virus and parainfluenza virus [J]. N Engl J Med, 2001, 344(25): 1917-1928.
[3]	王卫平. 儿科学[M]. 8版. 北京: 人民卫生出版社, 2014: 269-271.
[4]	尚云晓,黄英, 刘恩梅, 等. 雾化吸入重组人干扰素α-1b治疗小儿急性毛细支气管炎多中心研究 [J].中国实用儿科杂志, 2014, 11(29): 840-844.
[5]	Gadomski A M, Brower M. Bronchodilators for bronchiolitis[DB/OL]. Cochrance Database Syst Rev, 2010, (12). CD001266.
[6]	陈乐,汪艳,张群威,等. 氯雷他定联合利巴韦林治疗儿童反复呼吸道感染的疗效及对患儿细胞免疫功能的影响[J]. 安徽医药,2015,7(19):1393-1395.
[7]	王宇清,季伟.呼吸道常见病毒和新型病毒与儿童呼吸道感染的关[J]. 中华预防医学杂志,2011,45(3):266-269.
[8]	王艳芬. 静脉注射及吸入激素治疗毛细支气管炎疗效观察[J]. 山西医药杂志,2009,38(7):642-643.